AllStripes provides an update on the inclusion body myositis (IBM) research program and the video includes a step-by-step walkthrough...
The primary focus of Myositis Support and Understanding is muscle diseases which are referred to as “Idiopathic Inflammatory Myopathies” or “Acquired Myopathies,” meaning muscle diseases which are typically not inherited and are caused by the immune system attacking muscles, connective tissue, blood vessels, and/or the skin.
Third Annual “A Day of Remembrance” a video event to honor and remember those we have lost with myositis....
Educational and engaging discussion w/ Dr. Andrew Mammen around immune-mediated necrotizing myopathy (IMNM) and the phase 2 clinical trial...
Help researchers and clinicians better understand how patients with myositis and other autoimmune conditions feel about COVID-19/the novel coronavirus.
Managing Myositis Patient Care During the COVID-19 Public Health Crisis

Dr. Aggarwal answers patient-submitted questions about COVID-19 and myositis with topics including proper precautions to stay safe, information about...
Introducing High Fives from the Heart: #MyositisLIFE in a Pandemic World, our May 2020 Myositis Awareness Month. In May,...
Watch to learn about different types of orthotics and braces that may be helpful for people with myositis. We...
Clinical Trial of Arimoclomol in Inclusion Body Myositis during the COVID-19 Pandemic

Information from Orphazyme A/S about the Clinical Development of Arimoclomol in sIBM during the COVID-19 Pandemic. Read a statement...
How to Qualify for Social Security Disability Benefits with Myositis

Learn more about how to apply and qualify for Social Security Disability Benefits when living with the inflammatory myopathies,...
Helpful hints (not resolutions!) to start off the new year with a plan to work toward great mental health...
Arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis

Orphazyme's Arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis, an incurable rare progressively debilitating muscle-wasting disease...
Summary of Dysphagia in patients with sporadic inclusion body myositis: Management challenges

A summary of the review, including Coping Strategies provided by MSU International Science Advisor and IBM patient, Bill Tillier....
Watch "Surviving the Holidays with Myositis" a webinar on #MyositisLIFE. Learn tips to get through the holidays living with...
The Food and Drug Administration (FDA) regulates stem cell products in the U.S. and recently issued a warning about...
A Phase 2 Study of Zilucoplan in Patients with Immune-Mediated Necrotizing Myopathy

We are excited to announce our partnership with Ra Pharma for RA101495-02.202: A Phase 2 Study of Zilucoplan in...
Myositis Support and Understanding (MSU) partners with the University of Pittsburgh for a new NIH-sponsored study entitled, “Myositis Patient...
Announcing the Mary Jane DeLauder Memorial Fund for inclusion body myositis

Mary Jane's passion for welcoming and educating was well-known throughout the myositis community. That’s why we can think of...
Skin findings seen with myositis autoantibodies and treatment of skin in dermatomyositis

Dr. Victoria Werth joined us live online for a video education session titled, "Skin findings seen with myositis autoantibodies...
Second Annual “A Day of Remembrance” a video event to honor and remember those we have lost with myositis....
Join the Yale Inclusion Body Myositis Registry

The success of the Registry effort depends on the cooperative efforts of IBM patients around the world. The IBM...